InflaRx N.V annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
InflaRx N.V Stock-Based Compensation Growth & History (IFRX)
InflaRx N.V's stock-based compensation was €4.4M for fiscal 2025.
View full InflaRx N.V company overviewInflaRx N.V annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €4.4M | €378,832 | +9.32% |
| 2024 | 2024-12-31 | €4.1M | €651,318 | +19.08% |
| 2023 | 2023-12-31 | €3.4M | −€2.6M | −43.51% |
| 2022 | 2022-12-31 | €6.0M | €1.7M | +39.52% |
| 2021 | 2021-12-31 | €4.3M | €3.2M | +287.92% |
| 2020 | 2020-12-31 | €1.1M | −€5.7M | −83.65% |
| 2019 | 2019-12-31 | €6.8M | −€5.3M | −43.46% |
| 2018 | 2018-12-31 | €12.1M | €7.5M | +165.59% |
| 2017 | 2017-12-31 | €4.6M | €3.7M | +405.57% |
| 2016 | 2016-12-31 | €900,000 | €700,000 | +350.00% |
| 2015 | 2015-12-31 | €200,000 | — | — |
InflaRx N.V quarterly stock-based compensation
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €591,376 | −€508,624 | −46.24% |
| Q1 2026 | 2026-03-31 | €941,097 | — | — |
| Q4 2025 | 2025-12-31 | €260,246 | — | — |
| Q3 2025 | 2025-09-30 | €595,879 | — | — |
| Q2 2025 | 2025-06-30 | €1.1M | −€100,000 | −8.33% |
| Q2 2024 | 2024-06-30 | €1.2M | — | — |
InflaRx N.V stock-based compensation trends
Over the last five fiscal years, InflaRx N.V's stock-based compensation increased from €1.1M to €4.4M, a change of €3.3M. The latest reported quarter, Q2 2026, shows €591,376.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review InflaRx N.V source filings ↗